Netlist, Inc. (NASDAQ:NLST), a leading provider of high performance memory solutions for the cloud computing and storage markets, reported financial results for the first quarter ended March 29, 2014. Revenues for the first quarter ended March 29, 2014, were $7.0 million, compared to revenues of $6.0 million for the first quarter ended March 30, 2013. Gross profit for the first quarter ended March 29, 2014, was $2.0 million, or 28.4 percent of revenues, compared to a gross profit of $0.6 million, or 9.5 percent of revenues, for the first quarter ended March 30, 2013. Netlist, Inc. (NASDAQ:NLST) net profit margin is -47.00% and weekly performance is -13.42%. On last trading day company shares ended up $1.29. Analysts mean target price for the company is $3.00. Netlist, Inc. (NASDAQ:NLST) distance from 50-day simple moving average (SMA50) is -28.04%.
Ignyta, Inc. (NASDAQ:RXDX) an oncology precision medicine biotechnology company, announced company highlights and financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, net loss was $4.1 million, or $0.28 per share, compared with $1.0 million, or $1.55 per share, for the first quarter of 2013. Ignyta Inc (NASDAQ:RXDX) shares fell -5.45% in last trading session and ended the day on $7.11. Ignyta Inc (NASDAQ:RXDX) quarterly performance is -38.17%.
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, announced the appointment of John M. Limongelli, Esq., to the newly created position of Senior Vice President, General Counsel & Corporate Secretary, effective immediately. Trevena Inc (NASDAQ:TRVN) shares moved down -7.08% in last trading session and was closed at $4.46, while trading in range of $ 4.41 – $4.78. Trevena Inc (NASDAQ:TRVN) year to date (YTD) performance is -31.38%.
Uroplasty, Inc. (NASDAQ:UPI) a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, reported financial results for the fiscal 2014 fourth quarter and full year ended March 31, 2014. Total global revenue for the fiscal fourth quarter 2014 was $6.4 million, up 15% from the same quarter in the prior year. Total domestic net revenue grew 13% to $4.5 million, as compared with $4.0 million during the year ago period while net international revenue grew 20% to $1.8 million, as compared with $1.5 million the fiscal fourth quarter of the prior fiscal quarter. Uroplasty, Inc. (NASDAQ:UPI) ended the last trading day at $2.97. Company weekly volatility is calculated as 7.60% and price to cash ratio as 5.06. Uroplasty, Inc. (NASDAQ:UPI) showed a negative weekly performance of -9.73%.